Jason Kelly compensation by year
Ginkgo Bioworks Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $250,000 | $250,000 | $250,000 | $250,000 | $250,000 | $250,000 |
| Bonus | $414,841 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $9,854,097 | $380,479,776 | $0 | $0 | $0 | $5,454,049 |
| Option awards | $0 | $0 | $0 | $0 | $981,000 | $0 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $14,250 | $12,500 | $12,500 | $12,500 | $0 | $5,000 |
| Total | $10,533,188 | $380,742,276 | $262,500 | $262,500 | $1,231,000 | $5,709,049 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ginkgo Bioworks Holdings, Inc. DEF 14A filed April 29, 2026, accession 0001628280-26-028377, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Ginkgo Bioworks Holdings, Inc. filed document, accession 0001628280-26-028377. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 425,898 | $3,539,212 | — |
| RSU | 48,279 | $401,198 | — |
| RSU | 9,726 | $80,823 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Ginkgo Bioworks Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2025 proxy (filed April 29, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-19 | Sale | — | 45,682 | $10.14 | 129,065 |
| 2026-10-16 | Exercise or conversion | — | 25,790 | — | 174,747 |
| 2026-10-16 | Exercise or conversion | — | 55,694 | — | 148,957 |
| 2026-10-16 | Exercise or conversion derivative | — | 55,694 | — | 18,564 |
| 2026-10-16 | Exercise or conversion derivative | — | 25,790 | — | 283,677 |
| 2026-07-28 | Grant or award derivative | — | 74,258 | — | 74,258 |
| 2026-07-28 | Grant or award derivative | — | 309,467 | — | 309,467 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Ginkgo Bioworks’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jason Kelly · this page | Chief Executive Officer | $5,709,049 |
| Reshma Shetty | President and Former Chief Operating Officer | $3,479,364 |
| Steven Coen | Chief Financial Officer | $1,332,326 |
| Mark Dmytruk | Former Chief Financial Officer | $386,941 |
Board service
Ginkgo Bioworks board · FY2021–FY2025How this board is paid
Company policy: Ginkgo Bioworks pays directors a $45,000 cash retainer and $275,000 in Options. As stated in Ginkgo Bioworks's FY2025 proxy.
The full Ginkgo Bioworks compensation record
free company briefThis page is one person within Ginkgo Bioworks's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Ginkgo Bioworks proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Ginkgo Bioworks's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ginkgo Bioworks's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order DNA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.